MedTrace Logo

Efficacy and Safety of a Single Dose of Emodepside Compared to a Single Dose of Albendazole in Adolescents and Adults Infected With Trichuris Incognita

NCT07258173 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-05-08

No results posted yet for this study

Summary

The purpose of this clinical trial is to compare the efficacy and safety of emodepside with the standard treatment, albendazole, in adolescents (12 years and older) and adults infected with Trichuris incognita.

Conditions

  • Trichuris Infection

Interventions

DRUG

Emodepside

Treatment with 15 mg of emodepside

DRUG

Albendazole 400 mg

Treatment with 400mg of albendazole

Sponsors & Collaborators

  • Centre Suisse de Recherches Scientifiques en Cote d'Ivoire

    collaborator OTHER

  • Université Félix Houphouët-Boigny

    collaborator UNKNOWN

  • Bayer

    collaborator INDUSTRY

  • Jennifer Keiser

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-15
Primary Completion
2026-09-15
Completion
2026-09-15

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07258173 on ClinicalTrials.gov